drugset
drugset / Trial / NCT06723106

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

NCT06723106 ↗

Phase 1 Enrolling by invitation 144 enrolled Chugai Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

This is a long-term extension trial of RAY121 in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).

Timeline

Start
2024-12-09
Primary completion
2028-02-28
Completion
2028-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject RAY121 Unknown — Other

Indications

Behcet disease antiphospholipid syndrome autoimmune thrombocytopenia bullous pemphigoid dermatomyositis immune-mediated necrotizing myopathy